What are common zidovudine side effects?
In the pharmaceutical manufacturing and clinical export sector, Zidovudine (AZT) is recognized for its potent antiretroviral activity but also for its significant “Hematologic” and “Mitochondrial” side-effect profile. As a pharmacist and manufacturer at Healthy Life Pharma, I categorize these effects based on the physiological systems they impact.
For your Healthy Inc marketplace, understanding these is vital for providing technical support to B2B buyers who manage HIV clinics.
1. Hematologic Side Effects (The Bone Marrow Risk)
The most critical technical risk associated with Zidovudine is its impact on blood cell production.
Anemia (Low Red Blood Cells): This is the most common severe side effect. It often occurs after 2–4 weeks of therapy and can be profound, sometimes requiring blood transfusions.
Neutropenia (Low White Blood Cells): A decrease in neutrophils, which increases the patient’s vulnerability to bacterial infections.
Technical Monitoring: As a manufacturer, our dossiers recommend a Complete Blood Count (CBC) every 2 weeks during the initial 3 months of therapy.
2. Mitochondrial & Metabolic Side Effects
Zidovudine can interfere with mitochondrial DNA polymerase $\gamma$, leading to systemic issues:
Myopathy (Muscle Weakness): Long-term use can lead to muscle wasting and pain (myalgia), particularly in the proximal muscles.
Lactic Acidosis: A rare but life-threatening metabolic emergency where the blood becomes too acidic.
Hepatomegaly with Steatosis: Enlargement of the liver due to fat accumulation, which can lead to liver failure.
Lipoatrophy: The loss of subcutaneous fat, particularly in the face and limbs, which is a significant psychological burden for patients.
3. Common & Early-Stage Side Effects
These are often self-limiting and occur as the body adjusts to the medication:
| Side Effect | Frequency | Clinical Note |
| Nausea & Vomiting | Very Common | Usually subsides after the first 4 weeks of therapy. |
| Headache | Common | Can be managed with standard analgesics initially. |
| Insomnia | Frequent | Patients may report difficulty sleeping or vivid dreams. |
| Skin/Nail Pigmentation | Occasional | Bluish-brown bands on the fingernails or toenails (Melanonychia). |
The Manufacturer’s Perspective: Technical & Export
From the desk of Nishith Shah (CEO, Healthy Life Pharma):
Formulation Purity: At our Mumbai plant, we focus on minimizing Related Substances (Impurities) in our Zidovudine API. High impurity levels are technically linked to increased gastric irritation and nausea in the early stages of treatment.
Storage Warning: Zidovudine is light-sensitive. We utilize Opaque Blue/White Capsule Shells and Alu-Alu Cold Form Blistering to prevent photodegradation. If the drug degrades due to light exposure, the side-effect profile can become unpredictable.
B2B Strategy: Highlight that Healthy Inc provides Zidovudine in Fixed-Dose Combinations (FDCs) with Lamivudine. FDCs are technically superior because they reduce “Pill Burden,” which is the leading cause of non-compliance and subsequent side-effect mismanagement.